Skip to content

A randomized, double-blind, placebo-controlled trial research based on standard treatment about Yishenshugantang treating premature ovarian failure which is geared to liver depression and deficiency of the kidney syndrome

A randomized, double-blind, placebo-controlled trial research based on standard treatment about Yishenshugantang treating premature ovarian failure which is geared to liver depression and deficiency of the kidney syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008323
Enrollment
Unknown
Registered
2016-04-19
Start date
2016-05-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ovarian failure

Interventions

Treatment group:dehydroepiandrosterone and TCM drug granules
The control group:dehydroepiandrosterone and TCM granules simulation agent

Sponsors

Beijing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Aged 18-40; 2. Correspond to diagnosis standards of western medicine and traditional Chinese medicine (TCM) syndrome of liver depression and deficiency of the kidney; 3. No other clinical trials in the past four weeks; 4. Not taking Chinese or western medicine related to the disease in the past two months.

Exclusion criteria

Exclusion criteria: 1. Patients whose primary or secondary amenorrhea are caused by congenital reproductive organs dysplasia, acquired genital organ disease or genital injury; 2. Patients whose amenorrhea are caused by a thyroid dysfunction; 3. Patients who are allergic to a variety of drugs or the ingredients of this medicine; 4. Patients who have comorbidity of heart, liver, kidney, hematopoietic system or mentally ill; 5. Patients who can't meet the inclusive criteria, can't take medicine as requested, can't be distinguished the curative effect or can't provide complete data which may influence the curative effect judgement.

Design outcomes

Primary

MeasureTime frame
TCM score;Follicle-Stimulating Hormone;

Secondary

MeasureTime frame
the changes of menstruation;Luteinizing Hormone;estradiol;uterine size;endometrial thickness;ovarian size;basal body temperature;

Countries

China

Contacts

Public ContactXiuxiang Teng

Beijing Hospital of Traditional Chinese Medicine

tengxx@126.com+86 13717987052

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026